Brintellix (Major Depressive Disorder) Market Size, Share, Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast To 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023. Brintellix (vortioxetine) is a multimodal antidepressant that is indicated for the treatment of MDD and was co-developed by Lundbeck and Takeda. It gained FDA approval in October 2013 and EMA approval in December 2013. Brintellix launched in the US market in January 2014 and its launch in European markets is expected during the second half of 2014 (Lundbeck, press release, December 27, 2013). Read Complete Report with TOC: http://www.radiantinsights.com/research/brintellixmajor-depressive-disorder-forecast-and-market-analysis-to-2023 Scope - Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Brintellix including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Brintellix for the top eight countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of Brintellix performance
- Obtain sales forecast for Brintellix from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia) Table Of Content: 1 Table of Contents 5 1.1 List of Tables 7 1.2 List of Figures 7 2 Introduction 8 2.1 Catalyst 8 2.2 Related Reports 8 2.3 Upcoming Related Reports 10 3 Disease Overview 11 3.1 Etiology and Pathophysiology 11 3.1.1 Etiology 11 3.1.2 Pathophysiology 11 3.2 Classification 13 3.3 Symptoms and Subtypes of Major Depressive Disorder 15 3.4 Prognosis 16 3.5 Quality of Life 16 Browse All Reports of This Category @ http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare 4 Disease Management 17 4.1 Diagnosis and Treatment Overview 17 4.1.1 Diagnosis 17 4.1.2 Treatment Guidelines and Leading Prescribed Drugs 18 4.1.3 Clinical Practice 21 5 Competitive Assessment 26 5.1 Overview 26 6 Brintellix (Vortioxetine) 28 6.1 Overview 28 6.2 Efficacy 30 6.3 Safety 32 6.4 SWOT Analysis 33 6.5 Forecast 34 7 Appendix 35 7.1 Bibliography 35 7.2 Abbreviations 37 7.3 Methodology 39 7.4 Forecasting Methodology 39 7.4.1 Diagnosed MDD Patients 39 7.4.2 Percent of Drug-Treated Patients 39 7.4.3 General Pricing Assumptions 40
7.4.4 Individual Drug Assumptions 41 7.4.5 Generic Erosion 41 7.5 Physicians and Specialists Included in this Study 42 7.6 About the Authors 44 7.6.1 Analyst 44 7.6.2 Therapy Area Directors 44 7.6.3 Global Head of Healthcare 45 7.7 About GlobalData 46 7.8 Disclaimer 46 List of Tables Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10) 14 Table 2: Subtypes of Major Depressive Disorder 15 Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria 17 To Get Sample Copy of Report visit @ http://www.radiantinsights.com/research/brintellixmajor-depressive-disorder-forecast-and-market-analysis-to-2023#tabs-4 Table 4: Treatment Guidelines for Major Depressive Disorder 19 Table 5: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 2013 21 Table 6: Leading Treatments for MDD, 2013 27 Table 7: Product Profile - Brintellix 29 Table 8: Efficacy of Brintellix in Six-Week to Eight-Week Clinical Trials 31 Table 9: Safety of Brintellix - Five Most Frequently Reported Adverse Events 33 Table 10: Brintellix SWOT Analysis, 2014 33 Table 11: Global MDD Sales Forecasts ($m) for Brintellix, 2013-2023 34 Table 12: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 43 List of Figures Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons 13 Figure 2: Disease Management Model for Major Depressive Disorder 23 Figure 3: Major Depressive Disorder Treatment Algorithm 25
About Us Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of Ancillary services such as, research partnerships/ tie-ups and customized research solutions. Media Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Website: Radiant Insights Visit Our Blog: radiantri.blogspot.com